Active	Status	Sponsor type	Region	Phase	Filter
4 Active 2 Inactive 6 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Hennermann, Julia B
NCT04840667 / 2018-004689-32: A Study of Replagal in Treatment-naïve Adults With Fabry Disease	Terminated	3	17	Europe, Canada	REPLAGAL, SHP675	Shire	Fabry Disease	12/22	12/22
STARLIGHT, NCT04573023 / 2020-003200-14: A Phase III Study of JR-141 in Patients With Mucopolysaccharidosis II	Recruiting	3	80	Europe, US, RoW	JR-141, Idursulfase, JR-141 or Idursulfase	JCR Pharmaceuticals Co., Ltd., JCR Pharmaceuticals Co., Ltd.	Mucopolysaccharidosis II	01/26	01/26
NCT05106764: Early Detection of Fabry Disease	Active, not recruiting	N/A	50	Europe	No intervention	Takeda	Fabry Disease	04/24	04/24